Fundraising Overview - The company raised a total of RMB 1,156,905,698.60 after deducting issuance costs of RMB 4,670,375.54, with the net amount available for use being RMB 1,156,905,698.60 [1][4] - As of June 30, 2025, the company had utilized RMB 1,029,056,832.19 for fundraising projects, with a remaining balance of RMB 52,258.70 [1][4] Fund Management - The company has established a fundraising management system in compliance with relevant laws and regulations to ensure proper use and management of the funds [1][2] - A tripartite agreement for the special account storage of fundraising was signed with Guotai Junan Securities and Bank of China, ensuring dedicated management of the funds [2][3] Fund Usage - The company has not used any idle funds for working capital during the reporting period, and all funds have been allocated according to the approved projects [4][6] - The company approved the use of RMB 15,000,000 of temporarily idle funds for cash management, with a maximum of RMB 4,700,000 allocated for permanent working capital [5][8] Compliance and Reporting - The company has adhered to all legal and regulatory requirements regarding the use of fundraising, with no violations reported [6][7] - The board of directors and supervisory board confirmed that the information disclosed regarding the fundraising usage is timely, accurate, and complete [7][9]

Core Viewpoint - The company, Qingdao Haier Biomedical Co., Ltd., is set to hold a half-year performance briefing on August 28, 2025, to discuss its operational results and financial status for the first half of 2025, allowing investors to engage in a Q&A session [2][3]. Group 1: Meeting Details - The performance briefing will take place on August 28, 2025, from 13:00 to 14:00 [5]. - The meeting will be held at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [4][5]. - Investors can submit questions from August 21 to August 27, 2025, through the Roadshow Center website or via the company's email [6]. Group 2: Participation Information - Investors can participate in the briefing by logging into the Shanghai Stock Exchange Roadshow Center on the scheduled date and time [4][5]. - The company will address commonly asked questions during the briefing, ensuring transparency and engagement with investors [3][6]. - Contact information for the company's securities department is provided for further inquiries [6].

Core Viewpoint - The company has adjusted the maximum repurchase price of its shares from RMB 50.00 per share to RMB 49.5367 per share following the implementation of the 2024 annual profit distribution plan [1][2][3] Summary by Sections 1. Basic Information on Share Repurchase - The company plans to repurchase its shares using its own funds through the Shanghai Stock Exchange, with a total repurchase amount between RMB 100 million and RMB 200 million within 12 months from the board's approval date [1] 2. Reasons for Adjusting the Maximum Repurchase Price - The adjustment is due to the company's decision to distribute a cash dividend of RMB 4.7 per 10 shares to all shareholders, which affects the base for calculating the repurchase price [2][3] 3. Details of the Price Adjustment - The new maximum repurchase price is calculated as follows: (previous maximum price - cash dividend per share) / (1 + change in circulating shares ratio). The cash dividend per share is approximately RMB 0.4633 based on the total shares participating in the distribution [3] 4. Estimated Repurchase Quantity - With the adjusted maximum repurchase price of RMB 49.5367, the company estimates it can repurchase approximately 4.0374 million shares, representing about 1.27% of the total share capital, based on the upper limit of RMB 200 million [4] 5. Other Matters - Other aspects of the share repurchase plan remain unchanged, and the company will adhere to relevant regulations while making repurchase decisions based on market conditions [5]